Which semaglutide brand name is right for your weight-loss goal?

The decision you're actually making: which brand applies to you?

A question our prescribers hear most weeks is some version of "can I get Ozempic for weight loss instead?" It's understandable, Ozempic became a household name before Wegovy was widely available, and the active ingredient is identical. But UK licensing draws a firm line. Ozempic's authorisation covers type 2 diabetes management; Wegovy's covers weight management in adults with a BMI of 30 or above, or 27 or above where a weight-related condition such as high blood pressure or obstructive sleep apnoea is present. A prescriber who issues Ozempic for weight loss is working outside the product's licence, which changes the regulatory and liability picture entirely. If weight management is your goal, Wegovy is the relevant brand, and that framing should guide every comparison you read online.

The MHRA is explicit that GLP-1 medicines should not be used for cosmetic or quick-fix weight loss, and that semaglutide products are not interchangeable across indications without clinical assessment. You can find that position set out in the NHS semaglutide medicines page.

Wegovy injection, Wegovy tablet, two semaglutide brands for the same goal, different routes

Both carry the Wegovy name but they are separate licensed products with different dose schedules, different storage requirements and different trial evidence behind them.

The Wegovy injection is a once-weekly subcutaneous pen. The maintenance dose runs up to 2.4 mg, with a higher 7.2 mg dose now approved and a dedicated single-dose 7.2 mg pen confirmed by the MHRA in April 2026. The STEP 1 trial reported around 15% average body-weight reduction over 68 weeks at 2.4 mg. The 7.2 mg data suggested approximately 20.7% average loss over 72 weeks, approaching the results seen with the dual-agonist tirzepatide. You can explore the injection in more depth on the Wegovy overview page.

The Wegovy tablet became the first oral GLP-1 medicine authorised in the UK for weight management on 11 June 2026, the UK was first in Europe to grant that approval. The dose escalates from 1.5 mg through 4 mg and 9 mg to a 25 mg maintenance dose. Phase 3 data (OASIS 4, 64 weeks) showed around 13.6% average weight loss versus roughly 2.4% on placebo; among participants who stayed fully adherent, the figure was approximately 17%. One practical advantage many people value: the tablet needs no refrigeration, making travel simpler. If you want to compare the two formats side by side, the full semaglutide page sets out the detail.

Rybelsus, the oral semaglutide brand that is not for weight loss

This is worth spelling out because it causes genuine confusion. Rybelsus contains oral semaglutide at 3 mg, 7 mg and 14 mg, tablets licensed for type 2 diabetes, not weight management. None of those strengths are part of the Wegovy tablet schedule; the two products share a molecule but are authorised for different purposes and carry different dose ladders. Someone searching for semaglutide name brands will often find Rybelsus listed alongside Wegovy, and the assumption that any oral semaglutide can be used for weight loss follows naturally. It cannot, legally, in the UK. The Wegovy tablet schedule begins at 1.5 mg and reaches 25 mg, those numbers don't appear in the Rybelsus product literature at all.

For context on what's available through a clinically regulated private route, the weight-loss treatments overview covers the options that hold a UK weight-management licence. If cost is a factor in your thinking, the Wegovy pricing page explains what legitimate private treatment involves, worth reading before making any comparisons based on headline figures alone.

What "non-branded semaglutide" means, and why to treat it with caution

Alongside the three named brands, you may come across references to non-branded semaglutide or compounded semaglutide products, often at substantially lower prices. The MHRA has not authorised any compounded semaglutide product for weight management in the UK. Genuine Wegovy comes through Novo Nordisk's authorised UK supply chain. Fake pens have appeared in quantity: in 2025 MHRA enforcement seized around 20 million doses of illegally traded weight-loss medicines (worth roughly £45 million) and the first UK site manufacturing counterfeit tirzepatide pens was raided. Semaglutide has been targeted in the same way. Any supplier offering semaglutide without a prescription, via social media, or at prices far below the market rate is a red flag, and if you are unsure what a legitimate dose looks like, our page explaining 100 units of semaglutide can help you understand standard measurements before you buy. Report suspected illegal sellers via the MHRA Yellow Card scheme.

The safest route to any semaglutide brand is a GPhC-registered pharmacy you can verify on the GPhC register. At nume, every consultation is read by a named GPhC-registered Independent Prescriber (a real clinician, not automated logic) before anything is prescribed. If you'd like a prescriber to assess which option fits your situation, you can check your eligibility through a free consultation.